Adamis Pharmaceuticals Corp (ADMP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adamis Pharmaceuticals Corp (ADMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8005
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc, is a biopharmaceutical company that develops therapies in areas of respiratory disease and allergy. The company offers pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as insect stings, foods, medications and latex. It also offers pipeline products such as APC-2000 for the treatment of bronchospasms; APC-1000 and APC-4000 for the treatment of asthma and chronic obstructive pulmonary disease; and steroid product for the treatment of allergic rhinitis. The company has operations in Phoenix and San Diego. Adamis is headquartered in San Diego, California, the US.

Adamis Pharmaceuticals Corp (ADMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Adamis Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 9
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adamis Pharma Enters Into Licensing Agreement With 3M Company For Taper Dry Powder Inhaler Technology 11
Equity Offering 12
Adamis Pharma Rises USD40.2 Million in Public Offering of Shares 12
Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 13
Adamis Pharma Raises USD11 Million in Private Placement of Units 15
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 17
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 18
Adamis Pharma Raises USD11.5 Million in Public Offering of Shares 19
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 21
Adamis Pharma Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.5 Million 22
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 23
Debt Offering 24
Adamis Pharma Completes Private Placement Of Debentures For US$0.6 Million 24
Adamis Pharma Completes Private Placement Of Senior Convertible Note For US$0.5 Million 25
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For US$1 Million 26
Adamis Pharmaceuticals Corp – Key Competitors 27
Adamis Pharmaceuticals Corp – Key Employees 28
Adamis Pharmaceuticals Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 10, 2018: Adamis Pharmaceuticals announces second quarter 2018 financial results and business update 30
May 10, 2018: Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 32
Product Approvals 33
Jul 23, 2018: Adamis Pharmaceuticals adds sublingual erectile dysfunction product candidate to its pipeline 33
Dec 04, 2017: Adamis Pharmaceuticals Announces Submission of Investigational New Drug Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose 34
Other Significant Developments 35
Mar 15, 2018: Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update 35
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adamis Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Adamis Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 9
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adamis Pharma Enters Into Licensing Agreement With 3M Company For Taper Dry Powder Inhaler Technology 11
Adamis Pharma Rises USD40.2 Million in Public Offering of Shares 12
Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 13
Adamis Pharma Raises USD11 Million in Private Placement of Units 15
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 17
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 18
Adamis Pharma Raises USD11.5 Million in Public Offering of Shares 19
Adamis Pharma Raises USD5 Million in Private Placement of Preferred Stock 21
Adamis Pharma Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.5 Million 22
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For US$0.5 Million 23
Adamis Pharma Completes Private Placement Of Debentures For US$0.6 Million 24
Adamis Pharma Completes Private Placement Of Senior Convertible Note For US$0.5 Million 25
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For US$1 Million 26
Adamis Pharmaceuticals Corp, Key Competitors 27
Adamis Pharmaceuticals Corp, Key Employees 28
Adamis Pharmaceuticals Corp, Subsidiaries 29

List of Figures
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Adamis Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Adamis Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Adamis Pharmaceuticals Corp (ADMP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Calfrac Well Services Ltd (CFW):企業の財務・戦略的SWOT分析
    Calfrac Well Services Ltd (CFW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Elk Petroleum Ltd (ELK):石油・ガス:M&Aディール及び事業提携情報
    Summary Elk Petroleum Ltd (Elk) is an oil and gas company that explore, produce, and develops oil and gas properties. The company operates projects in Grieve oil field and Singleton oil field. Its Grieve oil field development project is a joint venture between the company and Denbury Resources, a pe …
  • Trina Solar Co Ltd:企業の戦略的SWOT分析
    Trina Solar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Spire Inc (SR):石油・ガス:M&Aディール及び事業提携情報
    Summary Spire Inc (Spire), formerly Laclede Group, Inc., is a public utility, which carries out the sale, marketing and retail distribution of natural gas. It also markets natural gas and related activities on a non-regulated basis. The company also conducts transportation of liquid propane; real es …
  • Sumitomo Chemical Co., Ltd.:企業の戦略・SWOT・財務分析
    Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Chemical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Campanile UK Ltd:企業の戦略・SWOT・財務分析
    Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alfa Group Consortium:企業の戦略的SWOT分析
    Alfa Group Consortium - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Clark Public Utilities:企業の戦略的SWOT分析
    Clark Public Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Grupo SATA:企業の戦略的SWOT分析
    Grupo SATA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Veracyte Inc (VCYT):企業の財務・戦略的SWOT分析
    Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products comprise Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It als …
  • Gleiss Lutz Hootz Hirsch GmbH:企業の戦略的SWOT分析
    Gleiss Lutz Hootz Hirsch GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Dongbu Corporation:企業の戦略・SWOT・財務情報
    Dongbu Corporation - Strategy, SWOT and Corporate Finance Report Summary Dongbu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hunt Oil Co:企業の戦略的SWOT分析
    Hunt Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Canada Life Ltd:企業の戦略・SWOT・財務情報
    Canada Life Ltd - Strategy, SWOT and Corporate Finance Report Summary Canada Life Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hoosier Energy Rural Electric Cooperative, Inc.:発電所・企業SWOT分析
    Hoosier Energy Rural Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, …
  • Adverum Biotechnologies Inc (ADVM):企業の財務・戦略的SWOT分析
    Summary Adverum Biotechnologies Inc (Adverum) formerly Avalanche Biotechnologies Inc, is a clinical-stage gene therapy provider. The company’s product pipeline includes AVDM-053, ADVM-022 and AVA-311. Its products are used for treatment of antitrypsin deficiency, hereditary angioedema, wet age-relat …
  • Boone Electric Cooperative:企業の発電所・SWOT分析2018
    Boone Electric Cooperative - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Jardine Lloyd Thompson Group plc:企業のM&A・事業提携・投資動向
    Jardine Lloyd Thompson Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jardine Lloyd Thompson Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • ShinMaywa Industries, Ltd.:企業の戦略・SWOT・財務情報
    ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Grupa Lotos SA (LTS):石油・ガス:M&Aディール及び事業提携情報
    Summary Grupa Lotos S.A. (Grupa Lotos) is an integrated energy company. The company carries out various activities such as the extraction and refining of crude oil; processing of petroleum into finished products; and the wholesale and retail distribution and sale of petroleum products. Its product p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆